IRVINE, Calif., Feb. 24 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it will participate at two investor conferences in March. ISTA's President and Chief Executive Officer Vicente Anido, Jr., Ph.D., will participate in a panel discussion at the RBC Capital Markets Healthcare Conference at 2:35pm ET on Tuesday, March 2, 2010, in New York City. ISTA's Chief Financial Officer Lauren Silvernail will present at 2:15pm ET on Tuesday, March 9, 2010, at the Cowen and Company 30th Annual Health Care Conference in Boston, MA. Both the panel discussion and presentation will be webcast.
To access live audio broadcasts of these presentations, or the subsequent archived recordings, log onto http://www.istavision.com. Please connect to the website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
ABOUT ISTA PHARMACEUTICALS
ISTA Pharmaceuticals is the fourth largest branded ophthalmic pharmaceutical business in the U.S. ISTA's four marketed products plus its product candidates include therapies for inflammation, ocular pain, allergy, glaucoma, and dry eye. The Company is developing a strong product pipeline to fuel future growth and market share, supporting its goal to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.
SOURCE ISTA Pharmaceuticals, Inc.
Advertisement
To access live audio broadcasts of these presentations, or the subsequent archived recordings, log onto http://www.istavision.com. Please connect to the website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
Advertisement
ABOUT ISTA PHARMACEUTICALS
ISTA Pharmaceuticals is the fourth largest branded ophthalmic pharmaceutical business in the U.S. ISTA's four marketed products plus its product candidates include therapies for inflammation, ocular pain, allergy, glaucoma, and dry eye. The Company is developing a strong product pipeline to fuel future growth and market share, supporting its goal to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.
SOURCE ISTA Pharmaceuticals, Inc.
